Bioviva offering experimental gene therapy treatments for myostatin inhibition and telomere extension

Bioviva is offering various gene therapy treatments for telomerase extension and to treat alzheimers and hardening of arteries.

BioViva is a new company offering experimental medical services in South America.

Bioviva offers gene therapy for a myostatin inhibitor (the specific gene is not disclosed), and it has been tried by one of the team members, experimenting on himself 5 years ago, with good results in a younger man.

In a 2012 paper by Blasco’s student Bruno Bernardes de Jesus, ordinary lab mice were given gene therapy with an “extra” telomerase gene spread to their cells by a genetically-engineered virus. the mice lived 13-24% longer, and the experimenters reported “remarkable beneficial effects on health and fitness, including insulin sensitivity, osteoporosis, neuromuscular coordination and several molecular biomarkers of aging.”

Their team includes

* a lab that provides genetically modified viruses with a gene payload, made to order. (This has now become a reliable and predictable technology.)

* A doctor who has experience with experimental gene therapy, and who had the courage to experiment on himself five years ago, with good outcome thus far.

* Sites in Colombia and Mexico where doctors will administer therapies for which there is not yet FDA approval.

* Most important, a Scientific Advisory Board that includes two of the most prominent, senior biochemists who developed the science of telomerase in the 1990s and before. They are Bill Andrews and Michael Fossel.

* What they offer is gene therapy with hTERT and a proprietary myostatin inhibitor “in the same family with GDF-11,” according to CEO Elizabeth Parrish.

EMBO Molecular Medicine - Telomerase gene therapy in adult and old mice delays aging and increases longevity without increasing cancer


Read more »